Is it fair for the government to pressure companies to provide compassionate access to new therapies when their own formal evaluation processes appear to be showing very little urgency when it comes to patient access?
Latest Video
New Stories
-
Reform was justified because a committee prioritising clinical considerations was 'culturally' problematic
January 4, 2026 - - Latest News -
AdAlta and SHcell launch cancer collaboration to progress breakthrough CAR-T therapy
January 2, 2026 - - Australian Biotech -
Cabinet documents from the year that led to transformational changes
January 1, 2026 - - Latest News -
US pricing push gets real with Australia included in comparison list
December 22, 2025 - - Latest News -
Parsimony has unfortunately become an enduring test of the institution's legitimacy
December 20, 2025 - - Latest News -
PBAC delivers a broad range of outcomes in November, including for obesity
December 20, 2025 - - Latest News -
Takeda’s next-generation psoriasis therapy delivers landmark Phase 3 results
December 19, 2025 - - Latest News

